Prostate Cancer

>

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Latest News

Neeraj Agarwal, MD, FASCO
Shifting Therapies to Earlier Settings Could Bolster Treatment Options in mHSPC and Oligometastatic Prostate Cancer

March 26th 2024

Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.

Robert Dreicer, MD, deputy director and director of solid tumor oncology in the Division of Hematology/Oncology, and professor of medicine and urology at the University of Virginia Cancer Center in Charlottesville
Looking Beyond PSA Is Key to Understanding Nuances of Prostate Cancer Treatment

March 25th 2024

Mary-Ellen Taplin, MD
Taplin Tackles Equitable Treatment in Prostate Cancer

March 24th 2024

Ahsan Arozullah, MD, MPH, Astellas
Enzalutamide Receives Positive EU CHMP Opinion for High-Risk Biochemically Recurrent nmHSPC

March 22nd 2024

Shanta Dhar, PhD, FRSC, Sylvester Comprehensive Cancer Center’s NanoTherapeutics Research Laboratory
Innovation Is the Answer to Making Progress Against Cancer

March 22nd 2024

Latest CME Events & Activities

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News